Taysha Gene Therapies (NASDAQ: TSHA - Get Free Report) and MediWound (NASDAQ: MDWD - Get Free Report

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology c

Wolfe Research analyst Kalpit Patel initiates coverage on Taysha Gene Therapies (NASDAQ:TSHA) wit

Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.13) per share which missed the

Goldman Sachs analyst Salveen Richter maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy an

Citizens analyst Silvan Turkcan reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Market Outp

Wall Street analysts changed outlook on top names. Wedbush raised Replimune's price target, Cana

Baird analyst Jack Allen maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform and rai

U.S. stock futures up, Nasdaq 100 futures gain 2%. H.B. Fuller shares dip 8.3% on earnings release a

Shares of Micron Technology Inc (NASDAQ: MU) surged in pre-market trading after reporting strong Q3

Gainers American Shared Hospital (AMEX:AMS) stock rose 14.2% to $1.61 during Wednesday's after-

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology co

BMO Capital analyst Keith Tapper maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform

B of A Securities analyst Tazeen Ahmad maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy a

Citizens analyst Silvan Tuerkcan maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Market Outp

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology c

U.S. stock futures mostly higher, Nasdaq futures gain 100+ points. Sophia Genetics (SOPH) falls afte

Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.12) per share which missed the

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology co

Canaccord Genuity analyst Whitney Ijem maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy a

Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.12) per share which missed the

Needham analyst Gil Blum reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains

Chardan Capital analyst Geulah Livshits maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy

First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to <22 years) in Q4

Citizens analyst Silvan Tuerkcan maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Market Outp

Chardan Capital analyst Geulah Livshits maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy

Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.09) per share which met the ana

Raymond James analyst Christopher Raymond initiates coverage on Taysha Gene Therapies (NASDAQ:TSH

Taysha Gene Therapies shares fall after regaining full rights to Rett syndrome drug TSHA-102 and fin

Needham analyst Gil Blum reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains

DALLAS, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the C

Previously disclosed 100% response rate across all 10 patients in Part A for pivotal trial primary e

Baird analyst Jack Allen maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform and rai

U.S. stocks were mixed, with the Dow Jones index falling more than 50 points on Thursday.

Needham analyst Gil Blum maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the

Breakthrough Therapy designation granted based on FDA's review of available clinical evidence of

Wells Fargo analyst Yanan Zhu maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Overweight and

Canaccord Genuity analyst Whitney Ijem maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy a

Chardan Capital analyst Geulah Livshits maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy

Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.09) per share which missed the